WO2009132234A3 - Medical devices, polymers, compositions, and methods for delivering a haloacetate - Google Patents

Medical devices, polymers, compositions, and methods for delivering a haloacetate Download PDF

Info

Publication number
WO2009132234A3
WO2009132234A3 PCT/US2009/041603 US2009041603W WO2009132234A3 WO 2009132234 A3 WO2009132234 A3 WO 2009132234A3 US 2009041603 W US2009041603 W US 2009041603W WO 2009132234 A3 WO2009132234 A3 WO 2009132234A3
Authority
WO
WIPO (PCT)
Prior art keywords
haloacetate
delivering
polymers
compositions
methods
Prior art date
Application number
PCT/US2009/041603
Other languages
French (fr)
Other versions
WO2009132234A2 (en
Inventor
Lian L. Luo
Michael E. Benz
Christopher M. Hobot
Suping Lyu
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to EP09735415A priority Critical patent/EP2280742A2/en
Publication of WO2009132234A2 publication Critical patent/WO2009132234A2/en
Publication of WO2009132234A3 publication Critical patent/WO2009132234A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Polymers, compositions, and medical devices useful for delivering (e.g., by local and/or sustained delivery) a haloacetate (e.g., dichoroacetate) to a tissue are disclosed herein. Such methods can be useful for treatment of diseases such as cancer.
PCT/US2009/041603 2008-04-25 2009-04-24 Medical devices, polymers, compositions, and methods for delivering a haloacetate WO2009132234A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09735415A EP2280742A2 (en) 2008-04-25 2009-04-24 Medical devices, polymers, compositions, and methods for delivering a haloacetate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4778308P 2008-04-25 2008-04-25
US61/047,783 2008-04-25
US12/429,046 2009-04-23
US12/429,046 US20090269390A1 (en) 2008-04-25 2009-04-23 Medical devices, polymers, compositions, and methods for delivering a haloacetate

Publications (2)

Publication Number Publication Date
WO2009132234A2 WO2009132234A2 (en) 2009-10-29
WO2009132234A3 true WO2009132234A3 (en) 2011-06-16

Family

ID=41215235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041603 WO2009132234A2 (en) 2008-04-25 2009-04-24 Medical devices, polymers, compositions, and methods for delivering a haloacetate

Country Status (3)

Country Link
US (1) US20090269390A1 (en)
EP (1) EP2280742A2 (en)
WO (1) WO2009132234A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8246876B2 (en) * 2008-08-18 2012-08-21 Cook Medical Technologies Llc Embolization particles and method for making same
CN105517580A (en) 2013-03-15 2016-04-20 马修·R·德勒埃 Imageable embolic microsphere
GB2519738A (en) 2013-09-06 2015-05-06 Biocompatibles Uk Ltd Radiopaque polymers
GB2521997A (en) 2013-09-06 2015-07-15 Biocompatibles Uk Ltd Radiopaque polymers
WO2021257784A1 (en) * 2020-06-18 2021-12-23 Verté Therapeutics, Llc Injectable meloxicam formulations

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2507327A1 (en) * 1974-02-20 1975-08-21 Fuji Photo Film Co Ltd Neutralisation layer for dye diffusion transfer receptive sheet - contg. low mol. carboxylic acid and polymeric binder
JPS60222846A (en) * 1984-04-20 1985-11-07 Dainippon Printing Co Ltd Ionizing radiation sensitive negative type resist material
WO1988001627A1 (en) * 1986-09-02 1988-03-10 Gaf Corporation Water soluble complex of a poly(vinylpyrrolidone) copolymer and d-threo-(1,1'-dihydroxy-1-p-nitrophenylisopropyl) dichloroacetamide
WO1999029305A1 (en) * 1997-12-05 1999-06-17 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6001386A (en) * 1995-09-27 1999-12-14 University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
WO2001005387A2 (en) * 1999-07-21 2001-01-25 Maria Strumillo Djaczenko Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic and menthol for topical application, uses and process for the preparation thereof
WO2003028623A2 (en) * 2001-10-03 2003-04-10 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
WO2006108276A1 (en) * 2005-04-11 2006-10-19 The Governors Of The University Of Alberta A method of treating cancer using dichloroacetate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3179562A (en) * 1961-08-23 1965-04-20 Du Pont Treatment of diabetes with alpha, alpha substituted acetic acid derivatives
US3951903A (en) * 1974-11-01 1976-04-20 Gte Sylvania Incorporated Modified polycarbonate resin
US4122188A (en) * 1976-12-28 1978-10-24 Vanderbilt University Treatment of hyperlipoproteinemia with a dichloroacetate salt
JPS6036410A (en) * 1983-08-08 1985-02-25 Unitika Ltd Preparation of donor of biodegradable drug
US4631294A (en) * 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
US5145945A (en) * 1987-12-17 1992-09-08 Allied-Signal Inc. Homopolymers and copolymers having recurring carbonate units
US5286815A (en) * 1992-02-07 1994-02-15 Minnesota Mining And Manufacturing Company Moisture curable polysiloxane release coating compositions
CA2202397C (en) * 1994-10-17 2002-07-16 Peter W. Stacpoole Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
US5587397A (en) * 1995-06-08 1996-12-24 Cypros Pharmaceutical Corporation Reduction of elevated blood lactate using twice-daily dichloroacetate
US7009034B2 (en) * 1996-09-23 2006-03-07 Incept, Llc Biocompatible crosslinked polymers
US6727284B2 (en) * 1997-10-03 2004-04-27 University Of Alberta Postsurgical treatment with dichloroacetate
FR2769626B1 (en) * 1997-10-15 1999-12-03 Elf Aquitaine Exploration Prod STABILIZATION OF THIOACETIC ACID
US6074660A (en) * 1998-04-20 2000-06-13 Ethicon, Inc. Absorbable polyoxaesters containing amines and/ or amido groups
DE10033855A1 (en) * 2000-07-12 2002-01-31 Hexal Ag Transdermal therapeutic system for long-term treatment of hypertension, containing dicarboxylic acid angiotensin converting enzyme inhibitor converted into salt or ester derivative to improve stability
CA2429624A1 (en) * 2000-11-21 2002-05-30 Michael P. Diamond Compositions for adhesion prevention
US6693133B1 (en) * 2002-10-07 2004-02-17 University Of Alberta Methods of cardioprotection using dichloroacetate in combination with an inotrope

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2507327A1 (en) * 1974-02-20 1975-08-21 Fuji Photo Film Co Ltd Neutralisation layer for dye diffusion transfer receptive sheet - contg. low mol. carboxylic acid and polymeric binder
JPS60222846A (en) * 1984-04-20 1985-11-07 Dainippon Printing Co Ltd Ionizing radiation sensitive negative type resist material
WO1988001627A1 (en) * 1986-09-02 1988-03-10 Gaf Corporation Water soluble complex of a poly(vinylpyrrolidone) copolymer and d-threo-(1,1'-dihydroxy-1-p-nitrophenylisopropyl) dichloroacetamide
US6001386A (en) * 1995-09-27 1999-12-14 University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
WO1999029305A1 (en) * 1997-12-05 1999-06-17 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO2001005387A2 (en) * 1999-07-21 2001-01-25 Maria Strumillo Djaczenko Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic and menthol for topical application, uses and process for the preparation thereof
WO2003028623A2 (en) * 2001-10-03 2003-04-10 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
WO2006108276A1 (en) * 2005-04-11 2006-10-19 The Governors Of The University Of Alberta A method of treating cancer using dichloroacetate

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERSIN R M ET AL: "DICHLOROACETATE AS METABOLIC THERAPY FOR MYOCARDIAL ISCHEMIA AND FAILURE", AMERICAN HEART JOURNAL, vol. 134, no. 5, PART 01, 1 November 1997 (1997-11-01), pages 841 - 855, XP001032583, ISSN: 0002-8703, DOI: DOI:10.1016/S0002-8703(97)80007-5 *
CARPOV, ADRIAN ET AL: "Sur la réaction du chlorure de chloroacétale avec le poly(alcool vinylique) [Reaction of chloroacetyl chloride with poly(vinyl alcohol)]", ANGEWANDTE MAKROMOLEKULARE CHEMIE, vol. 24, no. 322, 1972, pages 101 - 120, XP002618530, ISSN: 0003-3146 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1971, IL'ENKO, M. I.: "Effect of preparation No. 76 [poly(vinyl chloroacetate), quaternized by trimethylamine sulfate] on some indexes of a hemostatic system", XP002618483, retrieved from STN accession no. 1971:461832 Database accession no. 72:61832 *
HA K ET AL: "CONTROL OF LIQUID CRYSTAL PRETILT ANGLES BY CHEMICAL DERIVATIZATION REACTION OF POLYVINYL ALCOHOL FILMS", LIQUID CRYSTALS: AN INTERNATIONAL JOURNAL OF SCIENCE AND TECHNOLOGY, TAYLOR & FRANCIS, GB, vol. 31, no. 6, 1 June 2004 (2004-06-01), pages 753 - 757, XP001195459, ISSN: 0267-8292, DOI: DOI:10.1080/02678290410001690401 *
IL'ENKO, M. I.: "Effect of preparation No. 76 [poly(vinyl chloroacetate), quaternized by trimethylamine sulfate] on some indexes of a hemostatic system", SB. NAUCH. RAB., VOLGOGRAD. GOS. MED. INST., vol. 22, 1969, pages 145 - 46, XP008128465 *
INMAN J K: "SYNTHESES OF MACROMOLECULAR IMMUNOMODULATORS AND CONJUGATES EMPLOYING HALOACETYL REAGENTS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 685, 1 January 1993 (1993-01-01), pages 347 - 350, XP000647500, ISSN: 0077-8923, DOI: DOI:10.1111/J.1749-6632.1993.TB35887.X *
MAGAGNINI, PIER L. ET AL: "Sulla temperatura di transizione vetrosa di alcuni aceti di polivinile sostituiti [Glass-transition temperatures of some substituted poly(vinyl acetates)]", ANNALI DI CHIMICA, vol. 57, no. 7, 1967, pages 805 - 816, XP008131863, ISSN: 0003-4592 *
PORMALE, M. ET AL: "Kinetics of hydrolysis of poly(vinyl alcohol) and monochloroacetic acid esters in the presence of catalysts", LATVIJAS PSR ZINATNU AKADEMIJAS VESTIS, KIMIJAS SERIJA, no. 4, 1977, pages 424 - 429, XP008128507, ISSN: 0002-3248 *
PORMALE, M. ET AL: "Preparation and properties of chlorine-containing derivatives of poly(vinyl alcohol)", LATVIJAS PSR ZINATNU AKADEMIJAS VESTIS, KIMIJAS SERIJA, no. 5, 1973, pages 614 - 616, XP008128510, ISSN: 0002-3248 *

Also Published As

Publication number Publication date
US20090269390A1 (en) 2009-10-29
EP2280742A2 (en) 2011-02-09
WO2009132234A2 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
IN2012DN00971A (en)
IN2012DN02805A (en)
MX2018015635A (en) Compositions and methods for modulation of smn2 splicing in a subject.
MX343135B (en) Fumagillol type compounds and methods of making and using same.
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
MX342709B (en) Treatment of cancer.
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2010151698A3 (en) Steerable medical delivery devices and methods of use
IN2012DN02081A (en)
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2009108626A3 (en) Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2010088527A3 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
WO2009132234A3 (en) Medical devices, polymers, compositions, and methods for delivering a haloacetate
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2012024583A3 (en) Oxysterol compounds
EP2528440A4 (en) Substituted norindenoisoquinolines, syntheses thereof, and methods of use
WO2010100570A3 (en) Activated leukocyte composition
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09735415

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009735415

Country of ref document: EP